AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22240882 — intervention group
Group type: EXPERIMENTAL
Intervention: Total occlusive ionic silver‐containing dressing (TOISD) combination
Number of subjects: 166
Study 22240882 — intervention group
Group type: COMPARATOR
Intervention: No dressing (control group)
Number of subjects: 166
Study 19204598 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational walking, moderate recreational PA, and strenuous recreational PA
Number of subjects: 1092
Study 19204598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild recreational PA
Number of subjects: 1092
Study 19204598 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to strenuous recreational PA
Number of subjects: 1092
Study 19204598 — intervention group
Group type: EXPERIMENTAL
Intervention: Total recreational PA
Number of subjects: 1092
Study 19204598 — intervention group
Group type: EXPERIMENTAL
Intervention: Yard activities
Number of subjects: 1092
Study 19204598 — intervention group
Group type: EXPERIMENTAL
Intervention: Household activities
Number of subjects: 1092
Study 16948718 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standard of care plus consultation with a nurse
Number of subjects: 1352
Study 16948718 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standard of care plus consultation with a nurse and home visitor
Number of subjects: 1352
Study 16948718 — intervention group
Group type: COMPARATOR
Intervention: Current standard of physician care
Number of subjects: 1352
Study 14716266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hero 642
Number of subjects: 30
Study 14716266 — intervention group
Group type: COMPARATOR
Intervention: K3
Number of subjects: 30
Study 14716266 — intervention group
Group type: COMPARATOR
Intervention: Profile
Number of subjects: 30
Study 11740307 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3-g Cr.kg(‐1) body weight for the first 5 days, then 0.07-g Cr.kg(‐1) body weight)
Number of subjects: 30
Study 11740307 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30
Study 11740307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11740307 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation and Placebo
Number of subjects: 30
Study 9236571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine hydrochloride (160 mg/d)
Number of subjects: 415
Study 9236571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 8233288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 316
Study 3652281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (2 g single dose)
Number of subjects: 51
Study 3652281 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (two 200 mg doses daily for 7 days)
Number of subjects: 51
Study 31906976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia + CHO (6% maltodextrin)
Number of subjects: 8
Study 31906976 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia + Placebo
Number of subjects: 8
Study 31065701 — intervention group
Group type: EXPERIMENTAL
Intervention: SKIP (every other day feeding)
Number of subjects: 1400
Study 31065701 — intervention group
Group type: EXPERIMENTAL
Intervention: 4/3 (4 days feeding and 3 nonconsecutive fasting days)
Number of subjects: 1400
Study 31065701 — intervention group
Group type: EXPERIMENTAL
Intervention: 5/2 (5 days feeding and 2 nonconsecutive fasting days)
Number of subjects: 1400
Study 31065701 — intervention group
Group type: EXPERIMENTAL
Intervention: DAILY (every day feeding)
Number of subjects: 1400
Study 31065701 — intervention group
Group type: EXPERIMENTAL
Intervention: 4/3 and 5/2 feeding programs
Number of subjects: 1400
Study 28544490 — intervention group
Group type: EXPERIMENTAL
Intervention: No suction drain (study group)
Number of subjects: 176
Study 28544490 — intervention group
Group type: COMPARATOR
Intervention: Suction drain (control group)
Number of subjects: 176
Study 25136887 — intervention group
Group type: COMPARATOR
Intervention: IV adenosine (140 µg/kg/min)
Number of subjects: 100
Study 25136887 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus regadenoson injection (400 µg)
Number of subjects: 100
Study 23440173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask-Advise-Connect (AAC)
Number of subjects: 2052
Study 23440173 — intervention group
Group type: COMPARATOR
Intervention: Ask. Advise. Refer. (AAR)
Number of subjects: 2052
Study 21669426 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 600
Study 21669426 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 600
Study 18268247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1,200 mg/day)
Number of subjects: 170
Study 18268247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18268247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 170
Study 16564589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) with one submandibular gland spared
Number of subjects: 36
Study 16564589 — intervention group
Group type: COMPARATOR
Intervention: Intensity Modulated Radiotherapy (IMRT) with no submandibular gland spared
Number of subjects: 36
Study 16564589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) with contralateral submandibular gland spared
Number of subjects: 36
Study 12658027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diastolic blood pressure lowering (DBP < or = 85 mmHg and < or = 80 mmHg)
Number of subjects: 18790
Study 12658027 — intervention group
Group type: COMPARATOR
Intervention: Less aggressive target group (DBP < 90 mmHg)
Number of subjects: 18790
Study 10817799 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg intravenous administration)
Number of subjects: 23
Study 10817799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9007147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCP) administered for 28-42 days followed by menotropin treatment
Number of subjects: 42
Study 9007147 — intervention group
Group type: COMPARATOR
Intervention: Previous cycles (control group)
Number of subjects: 42
Study 9007147 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP treatment cycles
Number of subjects: 42
Study 1800877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (less than 100 micrograms/kg) combined with diazepam (less than 0.2 mg/kg)
Number of subjects: 16
Study 1800877 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of fentanyl combined with diazepam (greater than that used in Group I)
Number of subjects: 16
Study 1800877 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of fentanyl combined with diazepam
Number of subjects: 16
Study 6139120 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with pethidine
Number of subjects: 185
Study 6139120 — intervention group
Group type: COMPARATOR
Intervention: Diazepam with pethidine
Number of subjects: 185
Study 30849239 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 ml of 'BEET It sport®' NO3‐ shot containing 12.8 mmol or 800 mg of NO3‐
Number of subjects: 11
Study 30849239 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 11
Study 30849239 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 ml of 'BEET It sport®' NO3‐ shot
Number of subjects: 11
Study 31062253 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine 30 mg
Number of subjects: 150
Study 31062253 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin 300 mg
Number of subjects: 150
Study 31062253 — intervention group
Group type: COMPARATOR
Intervention: acetaminophen 1000 mg
Number of subjects: 150
Study 30576330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led liver health clinic
Number of subjects: 910
Study 30576330 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 910
Study 30576330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case finding
Number of subjects: 910
Study 30576330 — intervention group
Group type: EXPERIMENTAL
Intervention: GP referrals
Number of subjects: 910
Study 30576330 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT questionnaire mailouts
Number of subjects: 910
Study 27787564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules (72 mg total, equivalent to 20 ounces of cranberry juice) administered once a day
Number of subjects: 185
Study 27787564 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once a day
Number of subjects: 185
Study 27787564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 185
Study 24952712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ages and Stages Questionnaire (ASQ) at 3 years of age
Number of subjects: 203
Study 24952712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development, Second Edition (BSID-II) scores at 14 months
Number of subjects: 203
Study 24952712 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical history including growth, feeding, and complications
Number of subjects: 203
Study 24952712 — intervention group
Group type: COMPARATOR
Intervention: Type of shunt
Number of subjects: 203
Study 21771570 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression rate of 80 min(‐1)
Number of subjects: 20
Study 21771570 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression rate of 160 min(‐1)
Number of subjects: 20
Study 20213208 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC educational video in Spanish on a portable personal digital video display device, accompanied by a brochure and a patient-delivered reminder for their physician.
Number of subjects: 65
Study 20213208 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 65
Study 11207693 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm pulsed dye laser treatment
Number of subjects: 11
Study 11207693 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel sheeting (Control)
Number of subjects: 11
Study 9259163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 3028
Study 9259163 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 3028
Study 7518406 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant aprotinin
Number of subjects: 41
Study 7518406 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 3555062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 300 mg every 12 hours
Number of subjects: 34
Study 3555062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg every 12 hours
Number of subjects: 34
Study 3555062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin orally after initial intravenous therapy
Number of subjects: 34
Study 3555062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 34
Study 30047564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Velpatasvir (VEL) quantified using a novel LC–MS/MS method; dosage and duration not specified.
Number of subjects: 0
Study 30047564 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal standard (ledipasvir) used in the quantification method.
Number of subjects: 0
Study 30047564 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed method for plasma sample analysis.
Number of subjects: 0
Study 28551590 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (up to 16mg/day)
Number of subjects: 41
Study 28551590 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher standing diastolic BP as a moderator
Number of subjects: 41
Study 26200563 — intervention group
Group type: EXPERIMENTAL
Intervention: New BNR method using deep dorsal stitch
Number of subjects: 84
Study 26200563 — intervention group
Group type: COMPARATOR
Intervention: Standard 'tennis racket' BNR
Number of subjects: 84
Study 24124744 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methylene blue or nanogate carbon injected into tumor bed
Number of subjects: 77
Study 24124744 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 77
Study 20619727 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 16
Study 20619727 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16
Study 20619727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 16
Study 20619727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 16
Study 20619727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17687273 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine pretreatment
Number of subjects: 0
Study 17687273 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole pretreatment
Number of subjects: 0
Study 17687273 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 0
Study 17068687 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected bladder neck movement >=10 mm
Number of subjects: 48
Study 17068687 — intervention group
Group type: COMPARATOR
Intervention: Corrected bladder neck movement <10 mm
Number of subjects: 48
Study 12600250 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise
Number of subjects: 80
Study 12600250 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing exercise
Number of subjects: 80
Study 11196405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent, containing NaF 0.25 mg, xylitol 159 mg, sorbitol 153 mg)
Number of subjects: 122
Study 11196405 — intervention group
Group type: COMPARATOR
Intervention: Fluoride tablets (Fludent) crushed in food
Number of subjects: 122
Study 11196405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent)
Number of subjects: 122
Study 8620132 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 4684
Study 8620132 — intervention group
Group type: COMPARATOR
Intervention: Usual accident and emergency staff
Number of subjects: 4684
Study 1460493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole supplemented with exercise protocols
Number of subjects: 120
Study 1460493 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 120
Study 1460493 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in place and Bruce treadmill exercise at Stage 0 or 0.5
Number of subjects: 120
Study 1460493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce Stage 1 exercise supplementation
Number of subjects: 120
Study 28734907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral second generation antipsychotic
Number of subjects: 221
Study 28734907 — intervention group
Group type: COMPARATOR
Intervention: Long-acting injectable risperidone microspheres
Number of subjects: 221
Study 27179374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (MLE)
Number of subjects: 648
Study 27179374 — intervention group
Group type: COMPARATOR
Intervention: Lateral episiotomy (LE)
Number of subjects: 648
Study 25020050 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose MenC‐TT at 3 months
Number of subjects: 110
Study 25020050 — intervention group
Group type: COMPARATOR
Intervention: 1 or 2 doses of MenC‐CRM197
Number of subjects: 110
Study 25020050 — intervention group
Group type: COMPARATOR
Intervention: No primary MenC doses
Number of subjects: 110
Study 22251050 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked International Affective Picture System (IAPS) pictures eliciting disgust or fear as primes
Number of subjects: 0
Study 22251050 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of disgust or fear as primes
Number of subjects: 0
Study 22251050 — intervention group
Group type: EXPERIMENTAL
Intervention: Words 'disgust' or 'fear' as primes
Number of subjects: 0
Study 20397594 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect duty violations
Number of subjects: 0
Study 20397594 — intervention group
Group type: EXPERIMENTAL
Intervention: Imperfect duty violations
Number of subjects: 0
Study 20397594 — intervention group
Group type: COMPARATOR
Intervention: Manipulated information about an agent's mental intentions
Number of subjects: 0
Study 18415829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 microg BID
Number of subjects: 0
Study 18415829 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 microg BID
Number of subjects: 0
Study 16750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha and ribavirin for 48 weeks
Number of subjects: 98
Study 16750059 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 98
Study 16750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha and ribavirin for mild disease
Number of subjects: 98
Study 16750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b and ribavirin
Number of subjects: 98
Study 14572126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CPAP
Number of subjects: 21
Study 14572126 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 21
Study 10744089 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus fluorouracil and calcium folinate (irinotecan group)
Number of subjects: 387
Study 10744089 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and calcium folinate alone (no-irinotecan group)
Number of subjects: 387
Study 8624384 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric broad-spectrum antibiotic therapy
Number of subjects: 1951
Study 8624384 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of antibiotic therapy
Number of subjects: 1951
Study 8624384 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopeptides
Number of subjects: 1951
Study 8624384 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemically active antifungals
Number of subjects: 1951
Study 1307733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippes Loop D
Number of subjects: 319
Study 1307733 — intervention group
Group type: EXPERIMENTAL
Intervention: copper T 380
Number of subjects: 319
Study 1307733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu T 200 and 220
Number of subjects: 319
Study 1307733 — intervention group
Group type: EXPERIMENTAL
Intervention: copper 7
Number of subjects: 319
Study 1307733 — intervention group
Group type: EXPERIMENTAL
Intervention: T IUDs liberating progesterone or progestagens (Nor 8; Nor 2; Net 10)
Number of subjects: 319
Study 1307733 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐steroid anti‐inflammatory prostaglandin synthesis' inhibitors (500 mg of mefenamic acid or 250 mg of Naproxen thrice daily for 5 days)
Number of subjects: 319
Study 6365352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 0
Study 31257924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting height percentiles (3rd, 10th, 25th, 50th, 75th, 90th, and 97th) computed using LMS chartmaker
Number of subjects: 7961
Study 31257924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting height to height (StH:Ht) ratio
Number of subjects: 7961
Study 30134240 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow's milk protein-based formula (pHF)
Number of subjects: 25
Study 30134240 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed cow's milk protein-based formula (eHF)
Number of subjects: 25
Study 26872294 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT + MA (moderate-intensity walking every 20 min)
Number of subjects: 13
Study 26872294 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT + LA (light-intensity walking every 20 min)
Number of subjects: 13
Study 26872294 — intervention group
Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 13
Study 25204295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 839
Study 25204295 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no MBP)
Number of subjects: 839
Study 22268969 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of isoflavones daily from Soylife 40
Number of subjects: 176
Study 22268969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 21072892 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein
Number of subjects: 140
Study 21072892 — intervention group
Group type: COMPARATOR
Intervention: Regular liver treatment only
Number of subjects: 140
Study 18765394 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous continuous aortic flow augmentation (flow ≤1.5 L/min for up to 96 hours) plus medical therapy
Number of subjects: 168
Study 18765394 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 168
Study 15772912 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 1 mg
Number of subjects: 168
Study 15772912 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg
Number of subjects: 168
Study 15772912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 14764418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen-Mansfield Agitation Inventory (CMAI-long form)
Number of subjects: 140
Study 10411798 — intervention group
Group type: EXPERIMENTAL
Intervention: Esclim 0.025 mg 17beta‐estradiol per 24 hours
Number of subjects: 196
Study 10411798 — intervention group
Group type: EXPERIMENTAL
Intervention: Esclim 0.050 mg 17beta‐estradiol per 24 hours
Number of subjects: 196
Study 10411798 — intervention group
Group type: EXPERIMENTAL
Intervention: Esclim 0.100 mg 17beta‐estradiol per 24 hours
Number of subjects: 196
Study 10411798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 7551400 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 15
Study 7551400 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 15
Study 7551400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions (supine and semirecumbency)
Number of subjects: 15